

# Table of Contents

---

<b>Preface</b> .....	<b>vii</b>
<b>Transfusion Indications</b> .....	<b>1</b>
Whole Blood .....	1
Red Blood Cells .....	3
Platelets .....	6
Plasma .....	8
Cryoprecipitate .....	10
Granulocytes .....	10
Plasma Derivatives, Factor Concentrates, and Recombinant Clotting Factors .....	11
<b>Assessment and Treatment of Anemia</b> .....	<b>13</b>
Use of Iron in the Treatment of Anemia .....	13
Use of Erythrocyte-Stimulating Agents and Thrombopoietin .....	15
Use of Hyperbaric Oxygenation .....	17
<b>Preoperative Autologous Donation</b> .....	<b>19</b>
<b>Cell Salvage</b> .....	<b>20</b>
<b>Issues in Specific Clinical Situations</b> .....	<b>22</b>
Volume Resuscitation .....	23
Cardiology .....	24
Hepatic Surgery .....	25
Critical Care .....	25
Obstetrics/Gynecology .....	26
Orthopedic Surgery .....	27
Pediatrics/Neonates .....	33
<b>Applications of Point-of-Care Testing</b> .....	<b>38</b>
Anemia .....	38
Coagulation System Parameters .....	38
Platelet Function .....	39
Viscoelastic Hemostatic Assays .....	39
Platelet Crossmatch and Platelet Transfusions .....	41
Massive Transfusion .....	42
New Technologies .....	42
<b>PBM Metrics</b> .....	<b>43</b>
General .....	43
Engagement of the Transfusion Committee .....	44
Economics and Cost-Effectiveness .....	45
<b>PBM Program Development</b> .....	<b>46</b>
<b>Patient Blood Management Certification</b> .....	<b>48</b>
Education .....	48
Pretransfusion Testing .....	49

<b>Quality Systems in the Perioperative Setting</b> .....	<b>51</b>
<b>Pharmacologic Interventions</b> .....	<b>54</b>
Topical Hemostatic Agents .....	54
Direct Anticoagulant Reversal Agents .....	54
Antifibrinolytic Agents .....	55
Impact of Herbal/Alternative Medications .....	56
<b>Pharmacologic Interventions to Reduce Hemorrhage</b> .....	<b>58</b>
<b>Investigational Agents</b> .....	<b>59</b>
Oxygen Therapeutic Agents .....	59
Manufactured Platelet Agents .....	60